119141-88-7
119141-88-7 structure
- Name: Esomeprazole
- Chemical Name: esomeprazole
- CAS Number: 119141-88-7
- Molecular Formula: C17H19N3O3S
- Molecular Weight: 345.416
- Catalog: API Digestive system medication Inhibition of gastric acid secretion
- Create Date: 2018-09-16 17:56:28
- Modify Date: 2026-07-01 18:20:00
-
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
| Name | esomeprazole |
|---|---|
| Synonyms |
Esomrazole
(S)-5-Methoxy-2-((4-Methoxy-3,5-diMethylpyridin-2-yl)Methylsulfinyl)-1H-benzo[d]iMidazole ESOMRAZOLE , EC PELLETS EsomrazoleQ: What is Esomrazole Q: What is the CAS Number of Esomrazole MFCD06798050 5-Methoxy-2-(((4-Methoxy-3,5-diMethylpyridin-2-yl)Methyl)sulfinyl)-1H-benzo[d]iMidazole (S)-Esomrazole EsoMrazole EC Pellets Esomrazol Impurity F 1H-BenziMidazole,6-Methoxy-2-[(S)-[(4-Methoxy-3,5-diMethyl-2-pyridinyl)Methyl]sulfinyl] Omrazole S-Isomer S-enantiomer of omeprazole esomeprazolum 6-Methoxy-2-[(R)-(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1H-benzoimidazole 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole (S)-5-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole (Esomrazole Impurity) EINECS 201-212-8 6-Methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Esomrazole D3 K salt Esomrazole Monomer 5-Methoxy-2-(4-Methoxy-3,5-diMethyl-pyridin-2-ylMethanesulfinyl)-1H-benzoiMidazole 5-Methoxy-2-{(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benzimidazole Nexium 6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl) (5-methoxy-1H-benzimidazol-2-yl)[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfoniumolate 119-6 esomrazole:5-methoxy-2-((s)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-1h-benzIMIDAZOLE 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-1H-benzimidazole 6-Methoxy-2-{(S)-[(4-Methoxy-3,5-diMethyl-2-pyridinyl)Methyl]sulfinyl}-1H-benziMidazole EsoMaprozole Esomrazole //BP (Reld F) Esomrzole (-)-Omrazole esomeprazol (R)-5-Methoxy-2-(((4-Methoxy-3,5-diMethylpyridin-2-yl)Methyl)sulfinyl)-1H-benzo[d]iMidazole (-)-Omeprazole (S)-(-)-Omeprazole Esomeprazole (INN) perprazole (S)-Omeprazole Esomrazole(Mg) Esomrazole(Na、Mg) [14C]-(-)-Omeprazole (S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole (S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole Aisi'aomeilazuona Esomrazole Sodium Esomrazol (S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole (S)-Esomeprazole UNII-N3PA6559FT 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole |
| Description | Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
H+, K+-ATPase[1][2] |
| In Vitro | Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1]. Cell Viability Assay[1] Cell Line: MDA-MB-468 cells Concentration: 25 µM, 50 µM, 75 µM, 100 µM Incubation Time: 20 hours Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner. |
| In Vivo | Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2]. Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2] Dosage: 30 mg/kg, 300 mg/kg Administration: Oral gavage; daily; for 19 or 11 days Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 600.0±60.0 °C at 760 mmHg |
| Molecular Formula | C17H19N3O3S |
| Molecular Weight | 345.416 |
| Flash Point | 316.7±32.9 °C |
| Exact Mass | 345.114716 |
| PSA | 96.31000 |
| LogP | 2.17 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.669 |
| Hazard Codes | Xn |
|---|---|
| HS Code | 2933990090 |
|
~92%
119141-88-7 |
| Literature: Che, Guoyong; Xiang, Jing; Tian, Tian; Huang, Qingfei; Cun, Linfeng; Liao, Jian; Wang, Qiwei; Zhu, Jin; Deng, Jingen Tetrahedron Asymmetry, 2012 , vol. 23, # 6-7 p. 457 - 460 |
|
~%
119141-88-7 |
| Literature: WO2007/88559 A1, ; Page/Page column 9-10 ; |
|
~%
119141-88-7 |
| Literature: US2011/213155 A1, ; Page/Page column 2 ; |
|
~72%
119141-88-7 |
| Literature: Reddy, Lekkala Amarnath; Malakondaiah, Golla China; Babu, Karrothu Srihari; Bhattacharya, Apurba; Bandichhor, Rakeshwar; Himabindu, Vimmidi; Reddy, Padi Pratap; Anand, Ramasamy Vijaya Organic Process Research and Development, 2008 , vol. 12, # 1 p. 66 - 68 |
|
~%
119141-88-7 |
| Literature: US2005/267157 A1, ; Page/Page column 10-11 ; |
|
~%
119141-88-7 |
| Literature: EP1992619 A1, ; Page/Page column 17 ; |
| Precursor 5 | |
|---|---|
| DownStream 0 | |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |